Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690

NCT ID: NCT05669521

Last Updated: 2023-08-14

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-15
• Study Completion Date: 2023-09-30

Brief Summary

Patients expected to receive a 500 mg/m2 of Leucovorin by iv & 500 mg/m2 of Fluorouracil (5FU) by iv bolus for their Colorectal Cancer. The patients will receive a one-hour infusion of TK-90 or equivalent TK-90 placebo depending on randomization at 5 hours & 11 hours post 5-FU iv bolus. This treatment cycle will continue weekly for 6 weeks. The TK112690 dose will be 45 mg/kg.

Detailed Description

Patients expected to receive a 500 mg/m2 of Leucovorin by iv & 500 mg/m2 of Fluorouracil (5FU) by iv bolus for their Colorectal Cancer. The patients will receive a one-hour infusion of TK-90 or equivalent TK-90 placebo depending on randomization at 5 hours & 11 hours post 5-FU iv bolus. This treatment cycle will continue weekly for 6 weeks. The TK112690 dose will be 45 mg/kg.

• 24 patients will be randomized equally into 2 different groups: TK-90 treated or TK-90 placebo treated.
• Screening must be completed within 2 weeks.
• The treatment period for the study is 6 weeks.
• Study follow-up will be scheduled post two weeks of completion of last dose of Chemotherapy & TK-90
• Blinding: The study will be partially blinded. The patient and investigator as well as site personnel will be blinded as to whether TK-90 or TK-90 placebo is administered. The CRO, sponsor, and site pharmacist will know whether the patient was administered active drug or TK-90 placebo

Conditions

Mucositis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

TK112690

TK112690 treatment

Group Type: EXPERIMENTAL

TK-112690

Intervention Type: DRUG

TK112690 treatment Post 5-FU chemotherapy

Placebo

TK112690 formulation

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo treatment Post 5-FU chemotherapy

Interventions

TK-112690

TK112690 treatment Post 5-FU chemotherapy

Intervention Type: DRUG

Placebo

Placebo treatment Post 5-FU chemotherapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and female patients 18 to 75 years old (both inclusive) with a histologically or cytological confirmed diagnosis of colorectal cancer

2. Patient scheduled to receive bolus 5 FU along with LV as first line or subsequent therapy for treating locally advanced or residual or recurrent or metastatic colorectal cancer.

3. No prior systemic treatments for cancer (chemotherapy and/or radiotherapy) 4 weeks prior to screening.

4. Be able to read and understand and provide a signature or thumb impression on the Informed Consent Form (ICF) before entering the study.

5. No other concurrent, active, invasive malignancy.

6. ECOG performance status of 0 to 2.

7. Must have a life expectancy of at least 6 months.

8. No active angina or uncontrolled arrhythmia.

9. Not pregnant or nursing. Women of childbearing potential must have a negative serum pregnancy test at screening and on the day before dosing and must use medically acceptable methods of birth control. Acceptable methods of birth control include oral or transdermal contraceptives, condoms, spermicidal foam, IUD, progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or post-menopausal for more than or equal to 1 year, must be specified in the patient's medical history file and CRF.

10. Mucositis Grade less than or equal to 1 per WHO Scale and Xerostomia of Grade less than or equal to 2 per CTCAE

11. Adequate bone marrow function as per CTCAE V5, defined as follows:

i) Absolute neutrophil count more than or equal to 1500 cells/mm3 based upon CBC/differential obtained within 2 weeks prior to randomization ii) Platelets more than or equal to 100,000 cells/mm3 based upon CBC/differential obtained within 2 weeks prior to randomization iii) Hemoglobin more than or equal to 8.0 g/dl based upon CBC/differential obtained within 2 weeks prior to randomization (Note: The use of transfusion or other intervention to achieve Hgb more than 8.0 g/dl is acceptable).

12. Adequate hepatic function with bilirubin less than or equal to 1.5 x upper-normal limit (ULN), AST or ALT less than or equal to 3x ULN within 2 weeks prior to randomization

13. Adequate renal function with serum creatinine less than 1.5 mg/dl and creatinine clearance (CrC) more than or equal to 50 ml/min within 2 weeks prior to randomization determined by 24-hour collection or estimated by Cockcroft-Gault formula. CrC male is equal to [(140 - age) x (wt in kg)] / [(Serum Cr mg/dl) x (72)]. CrC female is equal to 0.85 x (CrCl male)

14. Normal serum calcium or normal corrected serum calcium within 2 weeks prior to randomization; formula for corrected calcium if albumin valued is below normal range: Corrected calcium (mg/dl) is equal to (4 - [patients albumin (g/dl)] x 0.8) + patient measured calcium (mg/dl).

Exclusion Criteria

1. An active infection including HIV/ HBV/ HCV infection.

2. Patients who have not fully recovered after prior surgery. (Patients who have had prior surgery and have fully recovered and patients who may have surgery in the future are eligible.)

3. Unstabilized or symptomatic brain metastasis (History of brain metastases allowed if disease has stabilized or improved after radiation and/or craniotomy).

4. Pregnant or nursing mother.

5. Prior history of a cerebrovascular accident or hemorrhage.

6. Congestive heart failure, as defined by New York Heart Association class III or IV.

7. Uncontrolled hypertension.

8. Active psychiatric/mental illness making informed consent or useful clinical follow-up unlikely.

9. Patients who have previously been enrolled into this study and subsequently withdrew.

10. Patient receiving other investigational agent(s).

11. Any systemic immunosuppressive medication/therapy (eg, other chemotherapy, steroids).

12. Any prohibited prior or concomitant therapy 2 weeks prior to enrollment.

13. Presence of any significant systemic illness, unstable or severe medical condition(s) that could put the patient at risk during the study, interfere with outcome measures, or affect compliance with the protocol procedures such as intercurrent infection and/or autoimmune disease, ie, any condition that compromises the immune system.

14. Known or suspected intolerance or hypersensitivity to the study materials (TK 90 and/or excipients or closely related compounds).

15. Patients that have a history of poor compliance in clinical research studies.

16. Patients that have participated in any other investigative clinical trial in the past 4 weeks.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

SIRO Clinpharm Pvt. Ltd.

UNKNOWN

Sponsor Role: collaborator

Tosk, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Emile Youssef, MD, PhD

Role: STUDY_DIRECTOR

Tosk, Inc.

Locations

Jawaharlal Nehru Cancer Hospital and Research Centre

Bhopal, Madhya Pradesh, India

Om Sai Onco Surgery Multispecialty Hospital Center

Kolhāpur, Maharashtra, India

B. J. Medical College and Sassoon General Hospital

Pune, Maharashtra, India

MTES Sanjeevan Hospital

Pune, Maharashtra, India

Saveetha Medical college Chennai

Chennai, Tamil Nadu, India

Countries

India

Other Identifiers

CLP-2690-0007

Identifier Type: -

Identifier Source: org_study_id